{"nctId":"NCT01318109","briefTitle":"Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan","startDateStruct":{"date":"2008-08"},"conditions":["Type 2 Diabetes Mellitus"],"count":288,"armGroups":[{"label":"Alogliptin 12.5 mg QD and metformin 500mg BID or 750mg TID","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Alogliptin and metformin"]},{"label":"Alogliptin 25mg QD and metformin 500mg BID or 750mg TID","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Alogliptin and metformin"]},{"label":"Metformin 500mg BID or 750mg TID","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin"]}],"interventions":[{"name":"Alogliptin and metformin","otherNames":["SYR-32","Glycoran"]},{"name":"Alogliptin and metformin","otherNames":["SYR-322","Glycoran"]},{"name":"Metformin","otherNames":["Glycoran"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Had been taking metformin at a stable dose regimen (500 mg/day twice daily after meal or 750 mg/day three times daily after meal) for at least 12 weeks prior to the initiation of the treatment period (Week 0).\n2. Had an glycosylated hemoglobin (HbA1c) of 6.5% or more and below 10.0% at 8 weeks after the initiation of the observation period (Week -4).\n3. Had an HbA1c difference between 4 weeks after the initiation of the observation period (Week -8) and 8 weeks after the initiation of the observation period (Week -4) being within 10.0%\\* of the value at 4 weeks after the initiation of the observation period (Week -8) (\\*rounded off to the first decimal place).\n4. Was receiving specific diet and exercise (if any) therapies during the observation period.\n\nExclusion Criteria:\n\n1. Had taken other diabetic medications than metformin within 12 weeks before the initiation of the treatment period (Week 0).\n2. With a history or symptoms of lactic acidosis.","healthyVolunteers":false,"sex":"ALL","minimumAge":"26 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Glycosylated Hemoglobin (Week 12).","description":"The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.54","spread":"0.562"},{"groupId":"OG001","value":"-0.64","spread":"0.488"},{"groupId":"OG002","value":"0.21","spread":"0.641"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glycosylated Hemoglobin (Week 2).","description":"The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.13","spread":"0.196"},{"groupId":"OG001","value":"-0.13","spread":"0.150"},{"groupId":"OG002","value":"0.06","spread":"0.197"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glycosylated Hemoglobin (Week 4).","description":"The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":"0.279"},{"groupId":"OG001","value":"-0.31","spread":"0.268"},{"groupId":"OG002","value":"0.09","spread":"0.302"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glycosylated Hemoglobin (Week 8).","description":"The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.49","spread":"0.488"},{"groupId":"OG001","value":"-0.56","spread":"0.404"},{"groupId":"OG002","value":"0.13","spread":"0.465"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (Week 2).","description":"The change between the value of fasting plasma glucose collected at week 2 and baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.2","spread":"21.10"},{"groupId":"OG001","value":"-23.2","spread":"24.17"},{"groupId":"OG002","value":"0.0","spread":"26.37"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (Week 4).","description":"The change between the value of fasting plasma glucose collected at week 4 and baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.8","spread":"25.28"},{"groupId":"OG001","value":"-23.5","spread":"26.05"},{"groupId":"OG002","value":"-2.2","spread":"23.37"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (Week 8).","description":"The change between the value of fasting plasma glucose collected at week 8 and baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.0","spread":"23.05"},{"groupId":"OG001","value":"-21.3","spread":"25.30"},{"groupId":"OG002","value":"-3.1","spread":"26.23"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (Week 12).","description":"The change between the value of fasting plasma glucose collected at week 12 or final visit and baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.0","spread":"23.23"},{"groupId":"OG001","value":"-23.1","spread":"27.84"},{"groupId":"OG002","value":"-0.8","spread":"32.20"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).","description":"The change between the value of blood glucose measured by the meal tolerance test collected at week 12 or final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.7","spread":"43.42"},{"groupId":"OG001","value":"64.2","spread":"34.76"},{"groupId":"OG002","value":"70.6","spread":"35.31"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":92},"commonTop":["Nasopharyngitis","Constipation","Diarrhoea","Headache","Conjunctivitis allergic"]}}}